Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Pancreatic cancer is almost invariably associated with mutations in the KRAS gene, most commonly KRASG12D, that result in a dominant-active form of the KRAS GTPase. However, how KRAS mutations promote pancreatic carcinogenesis is not fully understood, and whether oncogenic KRAS is required for the maintenance of pancreatic cancer has not been established. To address these questions, we generated two mouse models of pancreatic tumorigenesis: mice transgenic for inducible KrasG12D, which allows for inducible, pancreas-specific, and reversible expression of the oncogenic KrasG12D, with or without inactivation of one allele of the tumor suppressor gene p53. Here, we report that, early in tumorigenesis, induction of oncogenic KrasG12D reversibly altered normal epithelial differentiation following tissue damage, leading to precancerous lesions. Inactivation of KrasG12D in established precursor lesions and during progression to cancer led to regression of the lesions, indicating that KrasG12D was required for tumor cell survival. Strikingly, during all stages of carcinogenesis, KrasG12D upregulated Hedgehog signaling, inflammatory pathways, and several pathways known to mediate paracrine interactions between epithelial cells and their surrounding microenvironment, thus promoting formation and maintenance of the fibroinflammatory stroma that plays a pivotal role in pancreatic cancer. Our data establish that epithelial KrasG12D influences multiple cell types to drive pancreatic tumorigenesis and is essential for tumor maintenance. They also strongly support the notion that inhibiting KrasG12D, or its downstream effectors, could provide a new approach for the treatment of pancreatic cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies have demonstrated that genetic ablation of KRAS expression leads to cell cycle arrest and death in cell lines and potent tumor regressions in animal models of PDAC (5–7).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [7]
In the citing paper
“Extinguishing the expression of mutant Kras in the pancreas led to rapid tumor regression, thus demonstrating a critical role of Kras in tumor maintenance (73, 78).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [78]
In the citing paper
“Withdrawal of oncogenic Kras resulted in regression of invasive neoplasia, including regression of metastatic disease63–65.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [63]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Research works printed but not linked: 2
- Klimstra, 1994, Am J Pathol., 145, 1547
- Caldwell, Oncogene.
Cited by
Items 401–500 of 769
Stein, A. P., Saha, S., Liu, C., Hartig, G. K., Lambert, P. F., & Kimple, R. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100995 · Cited by 22
“These models are most often used to assess the impact of relevant oncogenic mutations to tumorigenesis and therapeutic response for a variety of human cancers including pancreatic ductal adenocarcinoma [29,30], soft-tissue sarcoma [31], lung adenocarcinoma [32], HNC [33] and many others.”
Targeting inflammation in pancreatic cancer: Clinical translation
Steele, C. W., Gill, N. A. K., Jamieson, N. B., & Carter, C. R. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i4.380 · Cited by 25
Jakubison, B. L., Schweickert, P. G., Moser, S. E., Yang, Y., Gao, H., Scully, K. M., Itkin‐Ansari, P., Liu, Y., & Konieczny, S. F. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12314 · Cited by 31
Du, W., di Magliano, M. P., & Zhang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682217 · Cited by 23
“Genetically engineered mouse models (GEMMs) that harbor pancreas-specific expression of oncogenic Kras, such as KC (LSL-Kras; p48/Pdx-1-Cre) (26) and iKras* model (p48-Cre; R26-rtTa-IRES-EGFP; TetO-Kras) (27), recapitulate the stepwise carcinogenesis process of humanPDA.”
BackgroundSelf-citationA Novel Ras Inhibitor (MDC-1016) Reduces Human Pancreatic Tumor Growth in Mice
Mackenzie, G. G., Bartels, L. E., ., G. X., Papayannis, I., Alston, N., Vranková, K., Ouyang, N., & Rigas, B. (2013) · Neoplasia · doi:10.1593/neo.131368 · Cited by 25
“During all stages of pancreatic carcinogenesis, Kras upregulates inflammatory and signaling pathways that mediate paracrine interactions between epithelia and their surrounding microenvironment, and these Kras-dependent pathways drive tumorigenesis [16].”
BackgroundSun, Y., Peng, W., He, W., Luo, M., Chang, G., Shen, J., Zhao, X., & Hu, Y. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0818-z · Cited by 25
Mottini, C., Tomihara, H., Carrella, D., Lamolinara, A., Iezzi, M., Huang, J. K.-L., Amoreo, C. A., Buglioni, S., Manni, I., Robinson, F. S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0187 · Cited by 38
Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma
Hayashi, H., Uemura, N., Liu, Z., Matsumura, K., Sato, H., Shiraishi, Y., & Baba, H. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700315 · Cited by 29
“Interestingly, inactivation of KRAS in confirmed precursor lesions and during progression to PDAC leads to tumor regression of those lesions, showing that KRAS is required for tumor cell maintenance (56, 58) (Figure 3).”
BackgroundObesity-Associated Cancers: Evidence from Studies in Mouse Models
Lee, H. (2022) · Cells · doi:10.3390/cells11091472 · Cited by 24
“Recently, Collins and colleagues developed a new mouse model of PDAC, the iKras model (Ptf1a-Cre;LSLrtTA;LSL-Trp53R172H;TetO-KrasG12D) [61].”
BackgroundUtilizing past and present mouse systems to engineer more relevant pancreatic cancer models
DeCant, B. T., Principe, D. R., Guerra, C. E., di Magliano, M. P., & Grippo, P. J. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00464 · Cited by 24
Pancreatic cancer heterogeneity and response to Mek inhibition
Pedersen, K., Bilal, F., Morales, C. B., Salcedo, M., Macarulla, T. M., Massó-Vallés, D., Mohan, V., Vivancos, A. P., Carreras, M.-J., Serres, X., et al. (2017) · Oncogene · doi:10.1038/onc.2017.174 · Cited by 23
Rozengurt, E., & Eibl, G. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i15.1797 · Cited by 22
Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS
Wang, D., Bi, Y., Hu, L., Luo, Y., Ji, J., Mao, A. H., Logsdon, C. D., Li, E., Abbruzzese, J. L., Li, Z., et al. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0333-7 · Cited by 23
Milton, C. K., Self, A. J., Clarke, P. A., Banerji, U., Piccioni, F., Root, D. E., & Whittaker, S. R. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1131 · Cited by 24
“Transgenic mouse models expressing oncogenic Kras have demonstrated that mutantKRAS is an important driver in pancreatic cancer, as switching off Kras signaling results in tumor regression (4).”
BackgroundPancreatic cancer, treatment options, and GI-4000
Hartley, M. L., Bade, N. A., Prins, P., Ampie, L., & Marshall, J. L. (2014) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2014.1004017 · Cited by 21
hnRNPA1/UP1 Unfolds KRAS G-Quadruplexes and Feeds a Regulatory Axis Controlling Gene Expression
Ferino, A., Marquevielle, J., Choudhary, H., Cinque, G., Robert, C., Bourdoncle, A., Picco, R., Mergny, J., Salgado, G. F. J., & Xodo, L. E. (2021) · ACS Omega · doi:10.1021/acsomega.1c05538 · Cited by 23
Immunotherapy and Pancreatic Cancer: A Lost Challenge?
Laface, C., Memeo, R., Maselli, F. M., Santoro, A. N., Iaia, M. L., Ambrogio, F., Laterza, M., Cazzato, G., Guarini, C., Santis, P. D., et al. (2023) · Life · doi:10.3390/life13071482 · Cited by 24
Langer, L., Binenbaum, Y., Gugel, L., Amit, M., Gil, Z., & Dekel, S. (2014) · International Journal of Computer Assisted Radiology and Surgery · doi:10.1007/s11548-014-1122-9 · Cited by 24
“Mice carrying these two mutations concomitantly develop PDAC that recapitulates the genetic makeup and pathological characteristics of human PDACs [19,20].”
BackgroundLi, C. O., Chen, D., Luo, M., Ge, M., & Zhu, J. (2014) · Biotechnology Journal · doi:10.1002/biot.201300321 · Cited by 26
Kim, Y., Choi, S. R., Shin, D., & Cho, K. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0424-2 · Cited by 20
Casique‐Aguirre, D., Briseño-Díaz, P., García‐Gutiérrez, P., la Rosa, C. H. G.-D., Barceinas, R. S. Q., Rojo‐Domínguez, A., Vergara, I., Medina, L. A., Correa‐Basurto, J., Bello, M., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-5142-7 · Cited by 23
Meyers, N., Gérard, C., Lemaigre, F. P., & Jacquemin, P. (2020) · Scientific Reports · doi:10.1038/s41598-020-62106-8 · Cited by 19
Metildi, C. A., Kaushal, S., Hoffman, R. M., & Bouvet, M. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.03.049 · Cited by 22
“[14] Collins MA, Bednar F, Zhang Y, et al.”
BackgroundDeng, L., Zhang, H., Zhang, Y., Luo, S., Du, Z., Lin, Q., Zhang, Z., & Zhang, L. (2021) · Biomaterials Science · doi:10.1039/d1bm00446h · Cited by 21
Self-citationFAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer
Davidson, C., Taggart, D., Sims, A. H., Lonergan, D. W., Canel, M., & Serrels, A. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01966-5 · Cited by 24
Zeppa, L., Aguzzi, C., Morelli, M. B., Marinelli, O., Giangrossi, M., Luongo, M., Amantini, C., Santoni, G., & Nabissi, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042001 · Cited by 22
“The PI3K/AKT/mTOR and RAF/MEK/ERK pathways, frequently activated in PDAC, are involved in mediating autophagy, apoptosis, and chemoresistance, and they are known to drive PDAC development and tumor maintenance [3].”
BackgroundChu, N. J., Anders, R. A., Fertig, E. J., Cao, M., Hopkins, A. C., Keenan, B. P., Popović, A., Armstrong, T. D., Jaffee, E. M., & Zimmerman, J. W. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0053 · Cited by 21
“Along with factors such as late diagnosis poor prognosis results from its complex tumor microenvironment (TME) composed of transformed epithelial cells and tumor-promoting stromal cells that renders PDA refractory to radiation, chemotherapies, and immunotherapies (2, 3).”
BackgroundBeta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition
Brannon, A., Drouillard, D., Steele, N. G., Schoettle, S., Abel, E. V., Crawford, H. C., & di Magliano, M. P. (2020) · Scientific Reports · doi:10.1038/s41598-020-67814-9 · Cited by 19
Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis—A connection to licensing nodes
Schneeweis, C., Wirth, M., Saur, D., Reichert, M., & Schneider, G. (2017) · Small GTPases · doi:10.1080/21541248.2016.1262935 · Cited by 23
“Furthermore, oncogenic KRAS is also required to maintain PDAC growth.(12,13) Therefore, analy-”
BackgroundKRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma
Than, M. T., O’Hara, M. H., Stanger, B. Z., & Reiss, K. A. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0519 · Cited by 23
Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance
Ajina, R., Malchiodi, Z. X., Fitzgerald, A. A., Zuo, A., Wang, S., Moussa, M., Cooper, C. J., Shen, Y. L., Johnson, Q. R., Parks, J. M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0272 · Cited by 25
“The pancreatic cancer myelosuppressive microenvironment has been shown to be derived by tumorintrinsic properties (5, 6).”
BackgroundBibliometric Analysis of Hotspots and Frontiers of Immunotherapy in Pancreatic Cancer
Xu, Q., Zhou, Y., Zhang, H., Li, H., Qin, H., & Wang, H. (2023) · Healthcare · doi:10.3390/healthcare11030304 · Cited by 25
Das, K. K., & Early, D. S. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0149-8 · Cited by 21
Pan, P., Zhu, Z. G., Oshima, K., Aldakkak, M., Tsai, S., Huang, Y., Dong, W., Zhang, J., Lin, C., Wang, Y., et al. (2020) · Food Frontiers · doi:10.1002/fft2.1 · Cited by 19
“To block PDAC carcinogenesis, it is necessary to target the Kras mutation or its effector pathways (48).”
BackgroundDibra, D., Mishra, L., & Li, S. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.001 · Cited by 24
Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216
Mohelníková-Duchoňová, B., Kočík, M., Duchonova, B. M., Brynychová, V., Oliverius, M., Hlavsa, J., Honsová, E., Mazanec, J., Kala, Z., Ojima, I., et al. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.55 · Cited by 20
Park, S., Kim, D., Wu, G. J., Jung, H., Park, J.-A., Kwon, H., & Lee, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s186606 · Cited by 19
Mir34a constrains pancreatic carcinogenesis
Hidalgo‐Sastre, A., Lubeseder–Martellato, C., Engleitner, T., Steiger, K., Zhong, S., Desztics, J., Öllinger, R., Rad, R., Schmid, R. M., Hermeking, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66561-1 · Cited by 19
Diehl, J. N., Hibshman, P. S., Ozkan‐Dagliyan, I., Goodwin, C. M., Howard, S. V., Cox, A. D., & Der, C. J. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.008 · Cited by 20
Tumour microenvironment and heterotypic interactions in pancreatic cancer
Velasco, R. M., García, A. G., Sánchez, P. J., Sellart, I. M., & Lobo, V. J. S.-A. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00875-8 · Cited by 19
“TAMs also produce TGF-β and IL-10, inhibiting cytotoxic T lymphocytes, Th1 and Th2 CD4 + T cells and upregulating Foxp3 in CD4 + T cells, a transcription factor fundamental for Treg cells.”
BackgroundInfluentialExploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer
Bryce, A. S., Dreyer, S. B., Froeling, F. E. M., & Chang, D. K.-F. (2022) · Cancers · doi:10.3390/cancers14215302 · Cited by 20
“Mouse models support the no‐ tion that oncogenic KRAS is a driver of PDAC and of fibroblast activation, and that fibro‐ blast activation is reversed upon inactivation of oncogenic KRAS [36,37].”
BackgroundIovanna, J., Marks, D. L., Fernández-Zapico, M. E., & Urrutia, R. A. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.12.004 · Cited by 18
Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma
Kimbara, S., & Kondo, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i33.7440 · Cited by 18
A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer
Henry, K. E., Dacek, M. M., Dilling, T. R., Caen, J. D., Fox, I. L., Evans, M. J., & Lewis, J. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1485 · Cited by 18
Singh, K., Pruski, M. A., Polireddy, K., Jones, N. C., Chen, Q., Yao, J., Dar, W. A., McAllister, F. M., Ju, C., Eltzschig, H. K., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1031-z · Cited by 18
The role of asparagine synthetase on nutrient metabolism in pancreatic disease
Tsai, C., Kilberg, M. S., & Husain, S. Z. (2020) · Pancreatology · doi:10.1016/j.pan.2020.08.002 · Cited by 21
Cinque, G., Ferino, A., Pedersen, E. B., & Xodo, L. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176237 · Cited by 18
“Recent studies have demonstrated that point mutations in the KRAS proto-oncogene are the initial step of the PDAC carcinogenesis [2].”
MicroRNAs as biomarkers and perspectives in the therapy of pancreatic cancer
Xia, T., Chen, X., & Zhang, Y.-N. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04233-y · Cited by 18
Self-citationLoftis, A. R., Santos, M. S., Truex, N. L., Biancucci, M., Satchell, K. J. F., & Pentelute, B. L. (2020) · ChemBioChem · doi:10.1002/cbic.202000201 · Cited by 16
Mathison, A., Kerketta, R., de Assuncao, T. M., Leverence, E. N., Zeighami, A., Urrutia, G., Stodola, T. J., di Magliano, M. P., Iovanna, J., Zimmermann, M. T., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02498-6 · Cited by 18
Transcriptional Profile of Human Pancreatic Acinar Ductal Metaplasia
Jiang, J., Hakimjavadi, H., Bray, J. K., Perkins, C. M., Gosling, A., daSilva, L., Bulut, G. B., Ali, J., Setiawan, V. W., Campbell‐Thompson, M., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.02.003 · Cited by 21
Yang, X., Rosa, F. G. L., Genova, E. E., Huber, K. M., Schaack, J. B., DeGregori, J. V., Serkova, N. J., Li, Y., Su, L., Kessler, E. R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074809 · Cited by 18
“Kras, a well-known oncogene, and p53, a notable tumor suppressor gene, are two well-studied tumorigenic genes that have been associated with lung [1,2] [3], pancreas [4,5] [6] and colon cancer [7].”
BackgroundGao, C., Chen, G., Zhang, D. H., Zhang, J., Kuan, S., Hu, W., Esni, F., Gao, X., Guan, J., Chu, E., et al. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.07.004 · Cited by 23
“It is firmly established that mutant Kras is a driver of PDAC initiation(9) and is required for the maintenance of pancreatic cancer in mice.(10) Despite its well-established role in PDAC, the underlying mechanisms bywhich oncogenic Kras drives PDAC initiation and progression are not fully understood and the downstrea…”
BackgroundPrognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies
Kato, S., Okamura, R., Sicklick, J. K., Daniels, G. A., Hong, D. S., Goodman, A. M., Weihe, E., Lee, S., Khalid, N. K., Collier, R., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32813 · Cited by 17
Fujita, Y., Matsuda, S., Sasaki, Y., Masugi, Y., Kitago, M., Yagi, H., Abe, Y., Shinoda, M., Tokino, T., Sakamoto, M., et al. (2020) · Cancer Science · doi:10.1111/cas.14268 · Cited by 18
Therapeutic agents for targeting desmoplasia: current status and emerging trends
Nandi, T., Pradyuth, S. K., Singh, A. K., Chitkara, D., & Mittal, A. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.008 · Cited by 21
Selective Labeling and Identification of the Tumor Cell Proteome of Pancreatic Cancer In Vivo
Azizian, N. G., Sullivan, D. K., Nie, L., Pardo, S., Molleur, D., Chen, J., Weintraub, S. T., & Li, Y. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00666 · Cited by 18
Relaxed initiation pausing of ribosomes drives oncogenic translation
Dong, L., Mao, Y., Zhou, A., Liu, X., Zhou, J. L., Wan, J., & Qian, S. (2021) · Science Advances · doi:10.1126/sciadv.abd6927 · Cited by 18
Becker, J. H., Metropulos, A. E., Spaulding, C., Marinelarena, A. M., Shields, M. A., Principe, D. R., Pham, T. D., & Munshi, H. G. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3574 · Cited by 17
“Mutational activation of the KRAS gene, critical for PDAC initiation and maintenance in mouse models (4, 5), is present in more than 90% of human PDAC tumors, with KRAS G12D mutation accounting for ∼ 45% of the KRAS mutants (6, 7).”
Prkci Regulates Autophagy and Pancreatic Tumorigenesis in Mice
Inman, K. S., Liu, Y., Scotti, M. L., Leitges, M., Krishna, M., Crawford, H. C., Fields, A. P., & Murray, N. R. (2022) · Cancers · doi:10.3390/cancers14030796 · Cited by 17
Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies
Osei‐Bordom, D., Serifis, N., Brown, Z. J., Hewitt, D. B., Lawal, G., Sachdeva, G. S., Cloonan, D. J., & Pawlik, T. M. (2022) · Surgical Oncology · doi:10.1016/j.suronc.2022.101803 · Cited by 18
Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer
Chuang, H.-C., Huang, P.-H., Kulp, S. K., & Chen, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.006 · Cited by 17
Lamin A/C Maintains Exocrine Pancreas Homeostasis by Regulating Stability of RB and Activity of E2F
Elenbaas, J. S., Cunha, J. B., Azuero-Dajud, R., Nelson, B., Oral, E. A., Williams, J. A., Stewart, C. L., & Omary, M. B. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.024 · Cited by 16
Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma
Thakur, G., Kumar, R., Kim, S.-B., Lee, S.-Y., Lee, S., & Rho, G. (2021) · Biomedicines · doi:10.3390/biomedicines9020178 · Cited by 23
“did not found any strong correlation between Hedgehog expression profile and KRAS mutation status in PDAC patients [118], regardless of previous PDAC studies [119].”
ResultPancreatic cancer, treatment options, and GI-4000
Hartley, M. L., Bade, N. A., Prins, P., Ampie, L., & Marshall, J. L. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1011017 · Cited by 17
Dietlein, F., & Eschner, W. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt539 · Cited by 17
Targeting reactive nitrogen species suppresses hereditary pancreatic cancer
Li, M., Chen, Q., Ma, T., & Yu, X. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702156114 · Cited by 17
Sinkala, M., Mulder, N., & Martin, D. P. (2018) · Oncotarget · doi:10.18632/oncotarget.25632 · Cited by 17
“Further, while tumours displaying KRAS-pathway alterations either alone or in combination with TP53 pathway alterations have a poor prognosis, it has been shown that tumours with more complex pathway disruptions tend to have even poorer outcomes [12, 14].”
BackgroundMessex, J. K., Adams, K. L., Hawkins, W. G., DeNardo, D. G., Bardeesy, N. M., Billadeau, D. D., & Liou, G. (2022) · Cancers · doi:10.3390/cancers14092153 · Cited by 15
Norgard, R. J., Budhani, P., O’Brien, S. A., Xia, Y., Egan, J. N., Flynn, B., Tagore, J. R., Seco, J., Peet, G. W., Mikucka, A., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0172 · Cited by 18
“Theresultsdemonstratedstrongdecreaseincellcyclepathways,consistent with reported function of KRAS inhibition (23, 24), while IFN γ and IFN α responses,inflammatoryresponse,andTNF α signalingwereupregulated (Fig.”
BackgroundResultAguirre, A. J., Stanger, B. Z., & Maitra, A. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1926 · Cited by 18
U1 Adaptors Suppress the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts
Tsang, A. T., Dudgeon, C., Yi, L., Yu, X., Goraczniak, R. M., Donohue, K., Kogan, S., Brenneman, M. A., Ho, E. S., Gunderson, S., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0867 · Cited by 15
“The limitations of using dendrimer based systems are: (1) toxicity at high doses, (2) the solubility of oligonucleotide:dendrimer complexes is significantly less than that of either component alone which limits effective dosing, and (3) commercial preparation of dendrimers lacks a source for cGMP-compliant synthesis a…”
BackgroundAkanuma, N., Liu, J., Liou, G., Yin, X., Bejar, K., Liu, C., Sun, L., Störz, P., & Wang, P. (2017) · Pancreas · doi:10.1097/mpa.0000000000000913 · Cited by 15
Models of pancreatic ductal adenocarcinoma
Dennaoui, R., Shrestha, H., & Wagner, K. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09989-9 · Cited by 21
One-shot dual gene editing for drug-resistant pancreatic cancer therapy
Won, E.-J., Park, H., Chang, S.-H., Kim, J. H., Kwon, H., Cho, Y., & Yoon, T. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121252 · Cited by 15
Takahashi, M., Mutoh, M., Ishigamori, R., Fujii, G., & Imai, T. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-012-0340-x · Cited by 18
Effect of arenobufagin on human pancreatic carcinoma cells
Wang, T., Zhuang, Z., Zhang, P., Wang, Y., Mu, L., Jin, H., Zhou, L., Ma, X., Liang, R., & Yuan, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6798 · Cited by 17
“Certain genetic studies have shown that K-Ras activation and mutation is necessary for the initiation of PC (26-28), and an inducible pancreas‑specific expression system was used to show that K-Ras expression is also required for tumor maintenance (29).”
Schofield, H. K., Tandon, M., Park, M.-J., Halbrook, C. J., Ramakrishnan, S. K., Kim, E. C., Shi, J., Omary, M. B., Shah, Y. M., Esni, F., et al. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.10.008 · Cited by 15
“Immunohistochemistry and Immunofluorescence Histology and immunohistochemistry studies, as well as periodic acid–Schiff and Gomori trichrome staining, were performed as previously described.(20) To prepare for staining, tissue was collected and fixed overnight in 10% neutral”
MethodTargeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer
Chu, P., Kulp, S. K., Bekaii‐Saab, T., & Chen, C. (2016) · Small GTPases · doi:10.1080/21541248.2016.1251383 · Cited by 15
“that such KRAS mutations not only play a crucial role in the initiation of pancreas carcinogenesis,(5-7) but also are required for tumor maintenance.(8,9) From a therapeutic perspective, oncogenic KRAS represents a clinically relevant target in pancreatic cancer.”
BackgroundSilencing the Killers: Paracrine Immune Suppression in Pancreatic Cancer
Cox, A. D., & Olive, K. P. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.029 · Cited by 14
“Indeed, acute loss of mutant KRAS in established pancreatic tumors results in rapid quiescence and involution of pancreatic tumor stroma (Collins et al., 2012).”
BackgroundFacts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations
Linette, G. P., Bear, A. S., & Carreno, B. M. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1212 · Cited by 14
MicroRNA-34 and gastrointestinal cancers: a player with big functions
Gao, W., Zhou, J., & Morshedi, M. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03338-w · Cited by 17
“All lesion types that are generated by the normal exocrine pancreas, including pancreatic ductal adenocarcinoma, ductal metaplasia, and pancreatic intraepithelial neoplasia, are due to a fibro-inflammatory setting induced by desmoplasia associated with pancreatic ductal adenocarcinoma [43].”
BackgroundDiagnostic value of selected markers and apoptotic pathways for pancreatic cancer
Słotwiński, R., & Słotwińska, S. M. (2017) · Central European Journal of Immunology · doi:10.5114/ceji.2016.65139 · Cited by 14
“It is also known that changes in the microenvironment are connected with oncogenic KRAS signaling [103].”
BackgroundZhang, J., Li, X., Lu, Y., Wang, G., & Ma, Y. (2023) · Cancers · doi:10.3390/cancers15123146 · Cited by 16
Hao, S., Qu, R., Hu, C., Wang, M., & Li, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s284032 · Cited by 15
RetractedTetracycline-Regulated Mouse Models of Cancer
Yeh, E. S., Vernon, A. E., Martin, H. L., & Chodosh, L. A. (2014) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069823 · Cited by 14
“Studies of PDA primarily focus on oncogenic Ras activation using either elastase or p48 promoters to drive transgene expression in an epithelial-specific manner within the pancreas (Guerra et al. 2007; Collins et al. 2012; Ying et al. 2012).”
BackgroundInfluentialNakkina, S. P., Gitto, S. B., Beardsley, J. M., Pandey, V., Rohr, M., Parikh, J. G., Phanstiel, O., & Altomare, D. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413175 · Cited by 15
“KRAS is a hallmark oncogene in PDAC tumorigenesis [11,32], although the co-operative role of MYC is still being elucidated [33].”
BackgroundNovel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer
Guo, D., Ye, L., Wu, W., Yu, X., & Jin, K. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023045 · Cited by 15
“Inactivation and deletion of the tumor suppressor genes SMAD4, CDKN2A, and TP53are associated with PanIN progression and invasiveness [9,10].”
Kumar‐Sinha, C., Wei, I. H., & Simeone, D. M. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283567f69 · Cited by 16
What’s new in treatment of pancreatic cancer: a patent review (2010–2017)
Ramos, M. C., Boulaiz, H., Griñán‐Lisón, C., Marchal, J. A., & Vicente, F. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1349106 · Cited by 15
“K-ras K-ras [19]; Raf, MAPK, Erk, PI3Ks, PDK-1 [20] p53 p53 [21] Growth factor EGF, EGFR [22]; FGF, FGFR [23], VEGF [24], IGF [25] EMT Wnt/β-catenin [26]; TNFα [27]; Notch [28]; Snail-1, Slug, E-cadherin [29]”
Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts
Ruess, D. A., Görgülü, K., Wörmann, S. M., & Algül, H. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0453-y · Cited by 15
“It is already detected in early premalignant lesions (pancreatic intraepithelial neoplasia) with a high frequency [97–99] and promotes the initiation and progression of pancreatic intraepithelial neoplasia [12, 100, 101].”
BackgroundHeterocellular crosstalk and architecture of the pancreatic tumour microenvironment
Arnold, F., Vecchio, A. D., Hussain, Z., & Sherman, M. H. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00905-9 · Cited by 17
Aronchik, I., Kar, S., Zhuang, Y., Ahler, E., Lai, L., Seshadri, V., Yang, Y. C., Bulle, A. S., Ménard, M., Nayak, B., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04537-w · Cited by 32
“MYC amplification was observed in ctDNA of patient 1, whereas elevated c-MET expression models genomic alterations in patients 9 and 16.”
Moser, R. D., Annis, J. E., Nikolova, O. H., Whatcott, C., Gurley, K. E., Méndez, E., Moran‐Jones, K., Dorrell, C., Sears, R. C., Kuo, C. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4222 · Cited by 12
The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells
Chen, M., Chen, M., Fu, Y., & Zhang, J. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154603 · Cited by 12
Natural products with anti-tumorigenesis potential targeting macrophage
Liu, H., Huang, M., Xin, D., Wang, H., Yu, H., & Pu, W. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155794 · Cited by 14
Mallangada, N., Vargas, J. M., Thomas, S., Digiovanni, M. G., Vaeth, B. M., Nemesure, M. D., Wang, R., LaComb, J. F., Williams, J. L., Golub, L. M., et al. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22830 · Cited by 12
“These Krasdependent pathways drive tumorigenesis [6].”
BackgroundInfluentialIQGAP1 Maintains Pancreatic Ductal Adenocarcinoma Clonogenic Growth and Metastasis
Li, J. H., McMillan, R. H., Begum, A., Gocke, C. B., & Matsui, W. H. (2018) · Pancreas · doi:10.1097/mpa.0000000000001198 · Cited by 13
“Copyright © 2018 Wolters Kluwer H mutations are thought to be initiating events in PDAC as they are found in pancreatic intraepithelial neoplasia lesions that are carcinoma precursors and can induce PDAC in genetically engineered mouse models.(3,4) In leukemia, multiple myeloma, and skin cancers, RASmutations can lead…”
Transportome Malfunctions and the Hallmarks of Pancreatic Cancer
Ling, Q., & Kalthoff, H. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_20 · Cited by 12
Heterogeneity in Pancreatic Cancer Fibroblasts—TGFβ as a Master Regulator?
Watt, D. M., & Morton, J. P. (2021) · Cancers · doi:10.3390/cancers13194984 · Cited by 14
Metadata
- Authors
- Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M.
- Affiliations
- University of Michigan (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2012-02-01
- Volume
- 122
- Issue
- 2
- Pages
- 639-653
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3266788
- OpenAlex
- W2018159884
- Cited by
- 770
- References
- 66
- Citations by year
- 2026: 40 · 2025: 41 · 2024: 53 · 2023: 63 · 2022: 71 · 2021: 80 · 2020: 51 · 2019: 43 · 2018: 54 · 2017: 69 · 2016: 56 · 2015: 45 · 2014: 52 · 2013: 41 · 2012: 11
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Pancreatic Cancer Action Network
- American College of Surgeons
- Vanderbilt University
- University of Pennsylvania
- University of Michigan
- National Institutes of Health (NIH T32, P30 DK, 5-T32-HD007515)
- National Cancer Institute (R01CA151588, P50CA130810, P50CA13810)
- National Institute of General Medical Sciences (T32GM07315, T32GM007315)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (5-T32-HD007515, T32HD007505)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, KRAS G12D, oncogenic KRAS, pancreatic carcinogenesis, tumor maintenance, p53, precancerous lesions, epithelial differentiation, Hedgehog signaling, inflammation, tumor microenvironment, tumor regression, KRAS inhibition
- MeSH terms
- Animals, Cell Differentiation, Cell Transformation, Neoplastic, Disease Models, Animal, Epithelial Cells, Humans, Mice, Transgenic, Pancreatic Neoplasms, Pancreatitis, Signal Transduction, Survival Rate, Proto-Oncogene Proteins p21(ras), Mice, Hedgehog Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.